Eli Lilly has not submitted a biologics license application for retatrutide, its investigational GIP/GLP-1/glucagon triple agonist, and explicitly plans to file only in the first quarter of 2027 after finalizing the manufacturing and quality data package. Phase 3 TRIUMPH trials have delivered strong efficacy signals, including mean weight reductions of 20–28% at 80 weeks across obesity and type 2 diabetes populations, yet these results arrived too late in 2026 to allow any realistic FDA review and approval before year-end. Standard or priority review timelines place a decision no earlier than late 2027 even under optimistic assumptions. The sole plausible path to a 2026 approval would require an unprecedented acceleration of filing and review processes that current regulatory and manufacturing realities do not support.